BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 19691367)

  • 1. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.
    Monchaud C; Marquet P
    Clin Pharmacokinet; 2009; 48(7):419-62. PubMed ID: 19691367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.
    McCune JS; Bemer MJ
    Clin Pharmacokinet; 2016 May; 55(5):525-50. PubMed ID: 26563168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.
    del Mar Fernández De Gatta M; Santos-Buelga D; Domínguez-Gil A; García MJ
    Clin Pharmacokinet; 2002; 41(2):115-35. PubMed ID: 11888332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients.
    Fruit D; Rousseau A; Amrein C; Rollé F; Kamar N; Sebbag L; Redonnet M; Epailly E; Marquet P; Prémaud A
    Clin Pharmacokinet; 2013 Apr; 52(4):277-88. PubMed ID: 23400901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation.
    de Jonge H; Naesens M; Kuypers DR
    Ther Drug Monit; 2009 Aug; 31(4):416-35. PubMed ID: 19536049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Benefit of therapeutic drug monitoring of immunosuppressants and immunomodulators in the management of autoimmune diseases].
    Djabarouti S; Mora P; Lahouati M; Gigan M; d'Houdain N; Sourisseau B; Chambord J; Xuereb F
    Rev Med Interne; 2022 Jul; 43(7):412-418. PubMed ID: 35643786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitors in pediatric renal transplant recipients.
    Filler G
    Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II.
    Monchaud C; Marquet P
    Clin Pharmacokinet; 2009; 48(8):489-516. PubMed ID: 19705921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
    Brunet M; van Gelder T; Åsberg A; Haufroid V; Hesselink DA; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard JB; Barten MJ; Budde K; Colom H; Dieterlen MT; Elens L; Johnson-Davis KL; Kunicki PK; MacPhee I; Masuda S; Mathew BS; Millán O; Mizuno T; Moes DAR; Monchaud C; Noceti O; Pawinski T; Picard N; van Schaik R; Sommerer C; Vethe NT; de Winter B; Christians U; Bergan S
    Ther Drug Monit; 2019 Jun; 41(3):261-307. PubMed ID: 31045868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2004; 43(10):623-53. PubMed ID: 15244495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.